Author

K. Yokote

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Cell Biology· 1 Immunology· 1 Pathology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 3 Assay:bulk RNA-seq· 2 Research Focus:host-pathogen & immune response· 2 Organism:mouse· 2 Research Focus:cell type annotation· 1 Research Focus:differential expression· 1 Organism:human· 1 Assay:proteomics· 1

Frequent Co-Authors

H. Nakajima· 2 shared K. Etori· 2 shared K. Hattori· 2 shared K. Ikeda· 2 shared S. Tanaka· 2 shared T. Kasuya· 2 shared Y. Maezawa· 2 shared A. Iwama· 1 shared

Activity by Year

2021-2022 · peak 2/yr

Co-Author Collaboration Network

10 top collaborators · 31 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

2 shared papersPathology

H. Nakajima

Mutual co-authors in cluster

Author profile →

3 papers

Recent·Most cited

Semaphorin 3G exacerbates joint inflammation through the accumulation and proliferation of macrophages in the synovium

J. Shoda, S. Tanaka, K. Etori, K. Hattori, T. Kasuya, K. Ikeda, Y. Maezawa, A. Suto, K. Suzuki, J. Nakamura, Y. Maezawa, M. Takemoto, C. Betsholtz, K. Yokote, S. Ohtori, H. Nakajima

This study identifies Semaphorin 3G as a factor that worsens joint inflammation by promoting macrophage accumulation and proliferation in RA synovium.

bioRxiv · Feb 12, 2022Pathology

Immunological features that determine the strength of antibody responses to BNT162b2 mRNA vaccine against SARS-CoV-2

T. Kageyama, S. Tanaka, K. Etori, K. Hattori, K. Miyachi, T. Kasuya, T. Iwamoto, K. Ikeda, H. Igari, K. Yokote, H. Nakajima

The paper identifies immunological features, including B cell frequencies and CD8+ T cell activation, that correlate with antibody response strength to the BNT162b2 mRNA vaccine.

bioRxiv · Jun 21, 2021Immunology

Stem cell therapy for skin regeneration using mesenchymal stem cells derived from the progeroid Werner syndrome-specific iPS cells

S. Funayama, H. Kato, H. Kaneko, K. Kosaka, D. Sawada, A. Takada-Watanabe, T. Minamizuka, Y. Baba, M. Koshizaka, A. Shimamoto, Y. Ouchi, A. Iwama, Y. Endo, N. Takayama, K. Eto, , K. Yokote

This study evaluates the efficacy of mesenchymal stem cells derived from Werner syndrome-induced pluripotent stem cells in treating skin ulcers, finding reduced angiogenic potential and improved healing with VEGF supplementation.

bioRxiv · Jun 15, 2021 · PreprintCell Biology